Minprostin (Dinoprostone)

Dinoprostone, the active ingredient in Minprostin, is a prostaglandin E2 analog presented as a vaginal formulation for intravaginal use. It is employed to soften the cervix and stimulate uterine contractions in obstetric settings. GNH USA supplies Minprostin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Minprostin is a prostaglandin E2 analog used in obstetrics for cervical and uterine management. - Cervical ripening: softens and dilates the cervix to prepare for labor. - Induction of labor: initiates uterine contractions when labor needs to be started. - Medical termination of pregnancy: facilitates fetal expulsion in early pregnancy termination procedures.

Adverse reactions may occur with intravaginal dinoprostone use.

Common Side Effects: - Uterine hyperstimulation: excessive contractions that may reduce fetal oxygenation. - Abdominal pain or cramping: discomfort in the lower abdomen. - Nausea and vomiting: gastrointestinal upset. - Diarrhea: loose stools. - Fever or chills: mild systemic response. - Vaginal bleeding: spotting or heavier flow.

Serious or Rare Side Effects: - Uterine rupture: tearing of the uterine wall, a medical emergency. - Severe hemorrhage: significant blood loss requiring intervention. - Fetal distress: abnormal heart rate patterns. - Allergic reaction: rash, itching, or anaphylaxis. - Cardiovascular collapse: sudden drop in blood pressure. - Pulmonary edema: fluid accumulation in the lungs.

Clinicians should observe specific safety measures when using Minprostin. - Cervical assessment: evaluate readiness before administration. - Fetal monitoring: continuously monitor fetal heart rate during treatment. - Prior cesarean section: avoid or use with extreme caution due to rupture risk. - Multiple gestation: consider increased risk of hyperstimulation. - Placenta previa or abruptio placentae: contraindicated. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Dinoprostone may interact with other agents affecting uterine activity or prostaglandin pathways.

Major Interactions (Avoid): - Oxytocin: combined use can cause severe uterine hyperstimulation. - Misoprostol: additive prostaglandin effect may lead to excessive contractions.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may diminish dinoprostone efficacy. - Tocolytic agents (e.g., nifedipine): can antagonize uterine stimulation. - Anticoagulants: increased risk of bleeding during cervical ripening. - Beta‑agonists: may alter uterine response to prostaglandins.